A Multi-Center, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon B-1a) to Natalizumab in Subjects with Relapsing Multiple Sclerosis

  • Berger, Joseph (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date5/17/10 → 1/31/12